Table 3

Descriptive statistics of pharmacokinetic parameters of capecitabine and its metabolites following single oral administration of 1255 mg/m2 of capecitabine

Geometric means (CV) are reported for Cmax and AUC0–∞; median values (min–max) are reported for tmax; arithmetic means (CV) are reported for t1/2 and urinary recovery (% of capecitabine dose).
ParameterCapecitabine5′-DFCR5′-DFUR5-FUFUH2FBAL
Cancer patients with normal hepatic function (n = 14)
Cmax (μg/ml)3.96 (71%)5.02 (53%)4.64 (54%)0.218 (61%)1.06 (26%)6.23 (41%)
tmax (h)2.00 (0.47–3.0)2.00 (0.57–4.0)2.00 (1.0–5.0)2.00 (1.0–3.0)3.00 (1.0–6.6)3.55 (2.0–6.6)
 AUC0–∞ (μg · h/ml)7.25 (48%)14.1 (30%)11.7 (25%)0.526 (29%)4.04 (32%)51.1 (43%)
t1/2 (h)0.73 (81%)0.95 (40%)0.94 (46%)0.98 (46%)1.26 (36%)11.5 (43%)
 Urinary recovery (% of dose)1.89 (37%)6.45 (46%)6.80 (44%)0.325 (93%)0.081 (158%)51.8 (25%)
Cancer patients with hepatic dysfunction (n = 13)
Cmax (μg/ml)5.91 (94%)3.56 (71%)6.19 (47%)0.280 (65%)1.16 (29%)6.74 (29%)
tmax (h)2.00 (1.0–4.0)2.00 (1.0–4.0)2.00 (1.0–4.0)2.00 (1.0–4.0)3.02 (1.0–5.0)3.02 (2.0–8.0)
 AUC0–∞ (μg · h/ml)10.7 (65%)9.15 (49%)14.0 (31%)0.606 (43%)4.15 (40%)63.2 (53%)
t1/2 (h)0.57 (33%)0.99 (42%)0.87 (37%)0.86 (35%)1.34 (26%)6.49 (29%)
 Urinary recovery (% of dose)3.45 (48%)5.38 (42%)6.14 (46%)0.468 (25%)0.263 (93%)56.7 (27%)